Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is pioneering mRNA cell therapy for the treatment of autoimmune diseases. The company leverages its proprietary technology and manufacturing platform to intr…
Analysis
Hope premium
Cartesian Therapeutics, Inc. is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium.
Valuation data is not available for this company.
Growth is moderate; the safety picture is adequate. The company scores 7/20 on our value-creation score: creating some value.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Mar 202623
51
2026
All-time high
51
Jun 2026
All-time low
23
Mar 2026
Average rank
37
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
36
—
—
—
Price/Earnings
16
—
—
—
Price/Book
70
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
56
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.